Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q3 2024 Ophthalmology Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q3 2024 Ophthalmology Update

The ophthalmology sector has been relatively quiet from an M&A perspective in recent quarters as many platforms have focused inward, prioritizing organic growth and optimizing internal operations to better position themselves for an
eventual exit. With more than half of the roughly 30 PE-backed platforms over five years into their respective hold periods, many groups will likely contemplate a sale in 2025, breaking the proverbial “log jam” in the space.

Given recent rate relief from the Fed and an expectedly robust secondary transaction market, Provident expects M&A volume to pick back up over the first half of next year. While larger private equity firms will be a landing spot for select platforms, national multispecialty consolidators are also likely to be potential buyers for groups in the secondary markets.

To print and download the full Ophthalmology Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/10/Q3-2024-Ophthalmology-Newsletter_vP.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]